title: Cutting-edge patents in Alzheimer's disease drug discovery: anticipation of potential future treatments.
abstract: Neurodegenerative disease broadly includes many different diseases, such as Alzheimer's, Parkinson's, amyotrophic lateral sclerosis, multiple sclerosis, Huntington's, dementias with Lewy bodies, post-traumatic brain injury, and stroke. Although few common physiopathological changes have been discovered among these conditions, the semiology (if known), the triggered molecular pathways that lead to the observed pathologies, and the symptomatology are essentially different. These differences entail that the treatments, both current and future, have disease-specific indications. This idea led us to believe than it would be quite impossible to comprehensively review the progress made in drug discovery for all the neurodegenerative diseases and, therefore, we focused our attention in this review on the cutting-edge patents that pertain to the treatment of Alzheimer's disease (AD). Basic science discoveries have identified new targets/leads that have led the scientific community to develop new research initiatives in order to develop novel therapeutics entities and approaches. The purpose of this review is to discuss, through cutting-edge patents, the emergence of potential future treatments of AD. We hope to provide the reader with a broader and better understanding of what could be new therapies for AD during the next decade.
authors.affiliation: Department of Biochemistry, Molecular and Cellular Biology, Georgetown University Medical Center, Washington DC, 20057, USA. ll55@georgetown.edu
authors.forename: Laurent
authors.initials: L
authors.lastname: Lecanu
authors.forename: Vassilios
authors.initials: V
authors.lastname: Papadopoulos
mesh_terms: D000544:Alzheimer Disease / Q000188:drug therapy*; D053829:Amyloid Precursor Protein Secretases / Q000037:antagonists & inhibitors; D016229:Amyloid beta-Peptides / Q000276:immunology; D016564:Amyloid beta-Protein Precursor / Q000378:metabolism; D000818:Animals; D002148:Calmodulin-Binding Proteins / Q000037:antagonists & inhibitors; D002614:Chelating Agents / Q000627:therapeutic use; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use; D015195:Drug Design; D038362:Glycogen Synthase Kinase 3 / Q000037:antagonists & inhibitors; D006801:Humans; D007114:Immunization; D010330:Patents as Topic; D000099291:Adducins
chemical_list: D053829:Amyloid Precursor Protein Secretases; D016229:Amyloid beta-Peptides; D016564:Amyloid beta-Protein Precursor; D002148:Calmodulin-Binding Proteins; D002614:Chelating Agents; D002800:Cholinesterase Inhibitors; D038362:Glycogen Synthase Kinase 3; C102021:ADD3 protein, human; D000099291:Adducins; C437846:AN-1792